catalog number :
MBS9419923
products type :
Recombinant Protein
products full name :
Recombinant Human EPO-a (rHu EPO-a)
products short name :
[EPO-a (rHu EPO-a)]
products name syn :
[rHu EPO-a, Epoetin]
products gene name :
[EPO-a]
sequence :
APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA WKRMEVGQQA VEVWQGLALL
SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK
LFRVYSNFLR GKLKLYTGEA CRTGDR
purity :
> 98% by SDS-PAGE and HPLC analyses.
form :
Lyophilized from a 0.2 um filtered concentrated solution in sodium citrate buffer (1 liter of ddH2O containing
5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid).
storage stability :
This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.
other info1 :
Target name: rHu EPO-a. Calculated MW: Mature human EPO, containing 1. SDS-PAGE WB: Sterile Filtered White lyophil
products description :
Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.